

Chris Plummer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9161306/publications.pdf>

Version: 2024-02-01

39
papers

1,551
citations

516710

16
h-index

330143

37
g-index

39
all docs

39
docs citations

39
times ranked

2349
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the European Association of Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International	7.1	364
2	6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet, The, 2019, 393, 2599-2612.	13.7	225
3	Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. British Journal of Cancer, 2009, 100, 684-692.	6.4	196
4	Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Annals of Oncology, 2009, 20, 816-827.	1.2	150
5	CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients "who is doing what to whom and how?". European Journal of Heart Failure, 2018, 20, 1039-1051.	7.1	107
6	Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer Journal, 2019, 9, 26.	6.2	71
7	Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. British Journal of Cancer, 2019, 121, 109-116.	6.4	38
8	Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. European Journal of Cancer, 2021, 148, 76-91.	2.8	33
9	Cardiotoxicity in Patients Treated With Bevacizumab Is Potentially Reversible. Journal of Clinical Oncology, 2011, 29, e560-e562.	1.6	31
10	Inequity of access to implantable cardioverter defibrillator therapy in England: possible causes of geographical variation in implantation rates. Europace, 2009, 11, 1308-1312.	1.7	29
11	A continuous patient activity monitor: validation and relation to disability. Physiological Measurement, 1997, 18, 49-59.	2.1	27
12	Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: A systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. European Journal of Cancer, 2021, 156, 127-137.	2.8	26
13	A novel algorithm increases the delivery of effective cardiac resynchronization therapy during atrial fibrillation: The CRTee randomized crossover trial. Heart Rhythm, 2018, 15, 369-375.	0.7	25
14	Trastuzumab-associated cardiac events in the Persephone trial. British Journal of Cancer, 2016, 115, 1462-1470.	6.4	23
15	Comparison of Sprint Fidelis and Riata defibrillator lead failure rates. International Journal of Cardiology, 2013, 168, 848-852.	1.7	21
16	The use of permanent pacemakers in the detection of cardiac arrhythmias. Europace, 2001, 3, 229-232.	1.7	17
17	The incidence of implantable cardioverter defibrillator indications in patients admitted to all coronary care units in a single district. Europace, 2005, 7, 266-272.	1.7	17
18	British Society for Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab. Echo Research and Practice, 2021, 8, G1-G18.	2.5	17

#	ARTICLE	IF	CITATIONS
19	Detection of Atrial Fibrillation by Permanent Pacemakers: Observations from the STOP AF Trial. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 333-340.	1.0	15
20	Implications of National Guidance for Implantable Cardioverter Defibrillation Implantation in the United Kingdom. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2003, 26, 479-482.	1.2	13
21	The patient journey from symptom onset to pacemaker implantation. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2008, 101, 955-960.	0.5	13
22	National Institute for Health and Care Excellence 2014 guidance on cardiac implantable electronic devices: health economics reloaded. <i>Europace</i> , 2015, 17, 339-342.	1.7	13
23	Delays and adverse clinical outcomes associated with unrecognized pacing indications. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2009, 102, 485-490.	0.5	12
24	Six versus 12 monthsâ€™ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-190.	2.8	11
25	Behind the scenes of the European Examination in General Cardiology. <i>Heart</i> , 2019, 105, 889-890.	2.9	8
26	Adherence to ESC cardiac resynchronization therapy guidelines: findings from the ESC CRT Survey II. <i>Europace</i> , 2020, 22, 932-938.	1.7	8
27	Chronic cardiovascular toxicity in the older oncology patient population. <i>Journal of Geriatric Oncology</i> , 2019, 10, 685-689.	1.0	7
28	Treatment specific toxicities: Hormones, antihormones, radiation therapy. <i>Seminars in Oncology</i> , 2019, 46, 414-420.	2.2	7
29	How to succeed in the EEGC: a guide for trainees and their trainers. <i>Heart</i> , 2019, 105, 1044-1045.	2.9	5
30	Aortic regurgitation and Churg-Strauss syndrome. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005, 98, 772-773.	0.5	4
31	Time to manual activation of implantable loop recorders--implications for programming recording period: a 10-year single-centre experience. <i>Europace</i> , 2009, 11, 1359-1361.	1.7	4
32	The European Society of Cardiology - A Digital Educator. <i>Journal of European CME</i> , 2021, 10, 2014039.	1.6	4
33	Unusual cause of hypoxemia after automatic implantable cardioverter-defibrillator leads extraction. <i>Annals of Cardiac Anaesthesia</i> , 2015, 18, 599.	0.6	3
34	What's in the CARDS?. <i>Diabetic Medicine</i> , 2006, 23, 711-714.	2.3	2
35	Implantable cardioverter defibrillator therapy for non-ischæmic cardiomyopathy. What is the role of programmed electrical stimulation?. <i>Europace</i> , 2009, 11, 273-275.	1.7	2
36	A survey of investigations performed prior to permanent pacemaker implantation. <i>Age and Ageing</i> , 2010, 39, 135-139.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Tunnelling defibrillator leads from the chest to the abdomen for chronic pain. <i>Europace</i> , 2013, 15, 844-844.	1.7	1
38	Sudden catastrophic pacemaker failure due to pacemaker generator malfunction: A rare but potentially fatal complication following permanent pacemaker implantation. <i>Resuscitation</i> , 2009, 80, 287-288.	3.0	0
39	Protective strategies to prevent trastuzumab-induced cardiotoxicity – Authors' reply. <i>Lancet</i> , The, 2020, 395, 492-493.	13.7	0